• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Cpmg Inc

    4/4/23 8:13:25 PM ET
    $APEN
    Industrial Specialties
    Health Care
    Get the next $APEN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
    X
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    CPMG Inc

    (Last) (First) (Middle)
    4215 WEST LOVERS LN., STE 100

    (Street)
    DALLAS TX 75209

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Apollo Endosurgery, Inc. [ APEN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) X Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    04/04/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/04/2023 D(3) 675,181 D (3) 0 I(1)(2) By Curlew Fund, LP(1)(2)
    Common Stock 04/04/2023 D(3) 1,310,701 D (3) 0 I(1)(2) By Killdeer Fund, LP(1)(2)
    Common Stock 04/04/2023 D(3) 3,687,781 D (3) 0 I(1)(2) By Roadrunner Fund, LP(1)(2)
    Common Stock 04/04/2023 D(3) 45,594 D (3) 0 I(1)(2) By Crested Crane, LP(1)(2)
    Common Stock 04/04/2023 D(3) 63,671 D (3) 0 I(1)(2) By Kestrel Fund, LP(1)(2)
    Common Stock 04/04/2023 D(3) 400,675 D (3) 0 I(1)(2) By Mallard Fund, LP(1)(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    CPMG Inc

    (Last) (First) (Middle)
    4215 WEST LOVERS LN., STE 100

    (Street)
    DALLAS TX 75209

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Desai Antal Rohit

    (Last) (First) (Middle)
    4215 WEST LOVERS LN., STE 100

    (Street)
    DALLAS TX 75209

    (City) (State) (Zip)
    Explanation of Responses:
    1. CPMG, Inc. is the investment manager of each of: Crested Crane, LP; Curlew Fund, LP; Kestrel Fund, LP; Mallard Fund, LP; Roadrunner Fund, LP; and Killdeer Fund, LP (the "Funds"). In such capacity, CPMG, Inc. may be deemed to have voting and investment power over the securities held directly by each of the Funds. Kent McGaughy, Jr. and Antal Desai, each of whom is a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares held directly by the Funds. Kent McGaughy, Jr. reports his beneficial ownership of these shares on a separate Form 4.
    2. Each of CPMG, Inc. and Mr. Desai (collectively, the "Reporting Persons") disclaims beneficial ownership of the securities reported herein except to the extent of its and his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.
    3. Reflects the disposition of the Reporting Persons' indirectly owned shares of the Issuer's common stock, par value $0.001 per share ("Issuer Common Stock"), upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 29, 2022, among the Issuer, Boston Scientific Corporation ("Parent") and Textile Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger between the Issuer and Merger Sub on April 4, 2023 (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer Common Stock was canceled and converted automatically into the right to receive $10.00 in cash, without interest (the "Merger Consideration"), less applicable taxes and authorized deductions.
    Remarks:
    Mr. McGaughy, Jr. serves on the Issuer's Board of Directors (the "Board") as a representative of CPMG, Inc. By virtue of his representation on the Board, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Persons may be deemed to be directors of the Issuer by deputization of Mr. McGaughy, Jr.
    /s/ John Bateman, Chief Operating Officer of CPMG, Inc. 04/04/2023
    /s/ Antal Rohit Desai 04/04/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $APEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APEN

    DatePrice TargetRatingAnalyst
    1/4/2023$10.00Buy → Hold
    Stifel
    11/30/2022$14.00 → $10.00Buy → Hold
    Lake Street
    2/23/2022$12.00 → $10.00Buy
    Stifel
    12/15/2021$13.00Outperform
    Cowen & Co.
    12/9/2021$12.00Buy
    Stifel
    9/9/2021$15.00Overweight
    Stephens
    More analyst ratings

    $APEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

      MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th

      2/1/23 6:30:00 AM ET
      $APEN
      $BSX
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Apollo Endosurgery Announces Two Important Milestones in the Advancement of Endoscopic Procedures for Patients Living with Obesity

      MERIT Trial Selected as 2022 Top Story in Gastroenterology and ASMBS adds Apollo Systems to List of Approved Bariatric DevicesAUSTIN, TX / ACCESSWIRE / December 13, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced today that the MERIT trial, published in The Lancet earlier this year(1), was selected as 2022 Top Story in Gastroenterology.(2) Additionally, the American Society for Metabolic and Bariatric Surgery (ASMBS) formally added four Apollo systems to its list of FDA Approved Bariatric Devices on December 5.(3) These milestones come only months after Apollo received FDA

      12/13/22 7:30:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery to be Acquired by Boston Scientific

      Boston Scientific to acquire Apollo for $10.00 per share in cashAUSTIN, TX / ACCESSWIRE / November 29, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a leading minimally invasive medical device company for gastrointestinal and bariatric procedures, announced today it has entered into a definitive merger agreement to be acquired by Boston Scientific Corporation ("Boston Scientific"), a global medical technology leader, in an all-cash transaction with an enterprise value of approximately $615 million.[1] This transaction has been unanimously approved by the Apollo Board of Directors.The acquisition price of $10.00 per share represents an approximate 67% premium to the closing price

      11/29/22 7:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Financials

    Live finance-specific insights

    See more
    • BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022

      MARLBOROUGH, Mass., Feb. 1, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $3.242 billion during the fourth quarter of 2022, growing 3.7 percent on a reported basis, 8.7 percent on an operational1 basis and 7.1 percent on an organic2 basis, all compared to the prior year period. Included within organic results is a negative approximately 200 basis point impact associated with unplanned reserves established for Italian government payback provisions3. The company reported GAAP net income available to common stockholders of $126 million or $0.09 per share (EPS), compared to $80 million or $0.06 per share a year ago and achieved adjusted4 EPS of $0.45 for th

      2/1/23 6:30:00 AM ET
      $APEN
      $BSX
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Apollo Endosurgery to Report Third Quarter Results on November 1, 2022

      AUSTIN, TX / ACCESSWIRE / October 18, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audi

      10/18/22 8:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery to Report Second Quarter Results on August 2, 2022

      AUSTIN, TX / ACCESSWIRE / July 21, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the second quarter ended June 30, 2022 on Tuesday, August 2, 2022, after market close.In conjunction with the release, Apollo will host a live webcast audio call with presentation slides at 3:30 p.m. CT / 4:30 p.m. ET to discuss the results. Investors are invited to join the live call via webcast from the Investors section of the Company's corporate website at www.apolloendo.com.An audio-only op

      7/21/22 8:00:00 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mcgaughy R Kent Jr

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 8:15:52 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Cpmg Inc

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 8:13:25 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Barr John R

      4 - Apollo Endosurgery, Inc. (0001251769) (Issuer)

      4/4/23 7:56:41 PM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Apollo Endosurgery Inc. (Amendment)

      SC 13G/A - Apollo Endosurgery, Inc. (0001251769) (Subject)

      5/8/23 11:07:57 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by Apollo Endosurgery Inc. (Amendment)

      SC 13D/A - Apollo Endosurgery, Inc. (0001251769) (Subject)

      4/4/23 8:50:48 PM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Apollo Endosurgery Inc.

      SC 13G - Apollo Endosurgery, Inc. (0001251769) (Subject)

      4/4/23 4:00:12 PM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Apollo Endosurgery Inc.

      15-12G - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/14/23 10:24:35 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Apollo Endosurgery Inc.

      EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/10/23 12:15:09 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • SEC Form EFFECT filed by Apollo Endosurgery Inc.

      EFFECT - Apollo Endosurgery, Inc. (0001251769) (Filer)

      4/10/23 12:15:16 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Leadership Updates

    Live Leadership Updates

    See more
    • MIMEDX Announces Leadership Transition

      K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., Sept. 06, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company"), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim Chief Executive Officer (CEO). Mr. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. M. Kathleen Behrens, Ph.D., Chairperson of MIMEDX's Board, said, "On behalf of the entire MIMEDX Board of Directors, I thank Tim for his contributions during an important time in MIMEDX's history and w

      9/6/22 7:00:00 AM ET
      $APEN
      $MDXG
      Industrial Specialties
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Apollo Endosurgery Appoints Jeannette Bankes to Board of Directors

      Veteran Brings 30 Years of Multinational Healthcare Leadership ExperienceAUSTIN, TX / ACCESSWIRE / April 4, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the appointment of Jeannette Bankes to its Board of Directors, bringing the number of board members to eight. Bankes is the President and General Manager of the Global Surgical Franchise at Alcon, a worldwide developer, manufacturer and marketer of eye care medical devices and ophthalmic products."Jeannette Bankes is a seasoned healthcare executive and board member known for applying her tremendous insight, experi

      4/4/22 7:15:00 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery Appoints Keely Scamperle as Vice President of Reimbursement and Market Access

      Veteran Leader Brings 25 Years of Global Medical Device ExperienceAUSTIN, TX / ACCESSWIRE / January 18, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced the hiring of Keely Scamperle as Vice President, Reimbursement & Market Access, effective January 17, 2022."At Apollo, we are addressing large unmet clinical needs in both gastroenterology and weight loss. We understand that developing products and procedures is only one component, and that facilitating patient access is a key element to successfully developing these markets," said Chas McKhann, president and CEO of A

      1/18/22 7:45:00 AM ET
      $APEN
      Industrial Specialties
      Health Care

    $APEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Apollo Endosurgery downgraded by Stifel with a new price target

      Stifel downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00

      1/4/23 7:13:09 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Apollo Endosurgery downgraded by Lake Street with a new price target

      Lake Street downgraded Apollo Endosurgery from Buy to Hold and set a new price target of $10.00 from $14.00 previously

      11/30/22 9:24:28 AM ET
      $APEN
      Industrial Specialties
      Health Care
    • Stifel reiterated coverage on Apollo Endosurgery with a new price target

      Stifel reiterated coverage of Apollo Endosurgery with a rating of Buy and set a new price target of $10.00 from $12.00 previously

      2/23/22 8:47:05 AM ET
      $APEN
      Industrial Specialties
      Health Care